[Vitreous fluorophotometry and nocturnal GH secretion in young insulin-dependent diabetics treated with oral pirenzepine].
With the aim of finding a correlation between the blocking of G.H. secretion and the irregularities in the permeability of the hematoretinal barrier, we have studied the average nocturnal G.H. levels (NAGHL) and the vitreous penetration rate (VPR) in five young diabetic patients. These patients, 3 males and 2 females, were between the ages of 12 and 17 years with a mean age of 16.0. They were studies both before and after receiving treatment for one month with an oral nocturnal dose of 0.6 mg/kg of pirenzepine (gastrozepin) and 1 mg/kg during the subsequent five months. We also tried to find a relationship between the VPR post-treatment and the evolution time of their illness and with their BA1C. The most important results found in this study were: 1) the nocturnal oral pirenzepine modified the NAGHL in the study population (10.48 +/- 4.94 vs; 4.34 +/- 2.53 ng/ml; p < 0.05). 2) Ingestion of the aforementioned drug did not affect the VPR (4.84 +/- 2.08 vs 4.53 +/- 2.54 x 10(-6)/min; p > 0.05). We have not found a relationship between the VPR after treatment with either the HBA1C levels or with the evolution time of the illness. Therefore, we conclude that the dose of oral pirenzepine used for 6 months, although it definitely decreases G.H. secretion, does not modify the permeability of the B.H.R. within this group of young diabetics. Hence, we can infer that the G.H. hypersecretion does not seem to have a relationship, at least exclusively, with the development of diabetic retinopathy.
Ruibal Francisco
J L
JL
Departamento de Pediatría, Hospital Universitario San Carlos, Madrid.
Benítez del Castillo
J M
JM
Seara Aguilar
G
G
Fernández Vila
P C
PC
Fernández Méndez
M
M
Reverte Blanc
F
F
García Sánchez
J
J
Casado de Frías
E
E
D000284:Administration, Oral; D000293:Adolescent; D002648:Child; D002940:Circadian Rhythm; D003922:Diabetes Mellitus, Type 1 / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D005260:Female; D015590:Fluorophotometry; D006442:Glycated Hemoglobin / Q000032:analysis; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D008297:Male; D010890:Pirenzepine / Q000008:administration & dosage*; D012044:Regression Analysis
D006442:Glycated Hemoglobin; D013006:Growth Hormone; D010890:Pirenzepine
Fluorofotometría vítrea y secreción nocturna de G.H. en jóvenes diabéticos insulino-dependientes tratados con pirenzepina oral.